Johnson & Johnson Will Pay $700 Million To Resolve Baby Powder Marketing Probe, Report SaysForbes • 01/08/24
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In ValueInvestors Business Daily • 01/08/24
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of CancerBusiness Wire • 01/08/24
Johnson & Johnson's Bullish Outlook: Surprising Strength You Shouldn't OverlookSeeking Alpha • 01/06/24
Johnson & Johnson - One Of The World's Safest Stocks Could Return +10% Per YearSeeking Alpha • 01/04/24
Johnson & Johnson: Rock Solid 3% Yield With Over 10% Return Potential (Rating Upgrade)Seeking Alpha • 01/04/24
Why one backer of MDMA therapy sees ‘exponential' growth following FDA approval this yearMarket Watch • 01/03/24